Phase 1 Lymphoma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older at the time of signing the consent form.
• People who are well enough to carry out some daily activities, as measured by standard medical performance scales (confirm with trial site).
• People who have been diagnosed with a type of B-cell lymphoma (a blood cancer affecting B-cells) that developed after receiving a solid organ transplant, where the cancer cells carry a marker called CD20, with or without a link to the Epstein-Barr virus (EBV).
• People whose cancer did not respond to a treatment that involved reducing anti-rejection medications (immunosuppression reduction), or where the treating doctor decided that approach was not appropriate.
• People whose cancer did not respond to a drug called rituximab, either alone or combined with chemotherapy.
• People who have measurable disease — meaning at least one tumour larger than 1.5 cm — and/or cancer found in the bone marrow.
• People who have received a transplant of a heart, lung, liver, kidney, pancreas, small intestine, or a combination of these organs.
• People living with HIV, provided the virus is undetectable in the blood, the CD4+ cell count is above 200 cells/uL, and the person is on ongoing antiviral treatment.
• People whose side effects from previous treatments have settled enough that participation is considered safe by the trial doctor.
• People whose expected survival is greater than 60 days.
• People whose blood counts and organ function test results meet specific minimum levels set by the trial (confirm with trial site for exact values).
• Women who could become pregnant must have a negative pregnancy blood test within 3 days before joining the trial.
• Women who could become pregnant must agree to use two forms of contraception, or to abstain from heterosexual activity, from the time of consent until 12 months after the last dose of the trial treatment.
• Male participants with female partners must have had a vasectomy or agree to use a double barrier contraception method from the first dose through to 12 months after the last dose.
• People who have had or currently have another cancer, as long as that cancer or its treatment is not expected to interfere with this trial's results, may be eligible (confirm with trial site).
• People who are able and willing to follow the trial procedures as judged by the trial doctor.

Who may not be able to join:

• People with an active infection that is not under control, though people on treatment for an infection that the trial doctor considers controlled may still be eligible.
• People who developed this type of lymphoma after a stem cell transplant (rather than a solid organ transplant).
• People who are pregnant or currently breastfeeding; stored breast milk cannot be used during treatment, and breastfeeding must stop while on the trial.
• People whose lymphoma has spread to the brain or spinal cord (central nervous system).
• People who require ongoing treatment for a seizure disorder.
• People with serious uncontrolled heart conditions, very high blood pressure, a heart attack within the past month, or uncontrolled seizures.
• People with a history of a serious brain condition called progressive multifocal leukoencephalopathy (PML).
• People with active Hepatitis B or Hepatitis C infection detected in the blood, though people with Hepatitis B who have an undetectable viral level and are on a specific suppression medication (entecavir) may be eligible, and people with a past Hepatitis C infection that is no longer detectable may also be eligible.
• People with a significant heart rhythm abnormality on an ECG at screening, unless the trial doctor confirms it is not medically important.
• People with any condition or abnormal test result that the trial doctor believes would put them at unacceptable risk or make it difficult to interpret the trial results.
• People who have received a live virus vaccine within 28 days before starting the trial treatment.
• People who have received another experimental treatment within 4 weeks or 5 half-lives (whichever is shorter) before starting the trial treatment, though this rule may not apply to certain experimental antibody therapies (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.